Inovio Pharmaceuticals announces successful trial of new DNA plasmid technology
The study, titled "Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein in Fab," sought to design a prototype monoclonal antibody able to fight the HIV virus. The study's researchers were able to successfully create an anti-HIV monoclonal antibody.
"What makes me particularly excited about this new published data is that, although early, the results clearly demonstrate the utility and potential of Inovio's patented DNA plasmid and electroporation technology to generate and develop a new class of active monoclonal antibody products with tremendous therapeutic and market potential," Inovio President and CEO Dr. J. Joseph Kim said. "These advancements represent a new area of value enhancement for Inovio stakeholders and we are now developing multiple important monoclonal product candidates.
"Inovio is one of the most innovative and scientifically productive biotechnology companies in our industry. Since the merger that created Inovio Pharmaceuticals over four years ago, we along with our collaborators have published over 70 peer-reviewed papers. At the same time we remain focused on the rapid development of our novel vaccines and immunotherapies for cancer and infectious diseases as well as attracting premier pharmaceutical partners to co-develop some of our product candidates."